• Research Use Only
  • Free shipping on orders over $300 USD
  • Premium research compounds
  • Third-party COA available
  • Secure checkout
  • Fast order processing
CAD
  • USD
  • CAD
  • EUR
CAD
  • USD
  • CAD
  • EUR

Cjc1295 Ipamorelin Vs Tesamorelin

CJC-1295 & Ipamorelin vs Tesamorelin — Research Comparison (2025–2026)

Mechanistic overview for Canadian research settings (non-medical, research-only)

Overview

CJC-1295/Ipamorelin and Tesamorelin are two of the most frequently compared peptide frameworks in Canadian research settings.

Both sit inside the growth hormone–related research category, but they operate through different receptors, pathways, and study designs:

✔ CJC-1295 + Ipamorelin → combo of GHRH analogue + GHRP (GHSR-1a agonist)
✔ Tesamorelin → GHRH analogue with its own distinct structure and pharmacokinetic profile

This comparison guide is designed for Canadian labs and academic teams who want a clean, mechanistic overview without hype, claims, or off-label discussion.

What Is CJC-1295 / Ipamorelin?

CJC-1295 is a long-acting GHRH analogue, designed to stimulate the body’s own growth hormone release by binding to GHRH receptors in the pituitary.

Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor (GHSR-1a).

When combined in research models, CJC-1295 + Ipamorelin provide a dual-pathway stimulation:

  • GHRH receptor activation (CJC-1295)
  • Ghrelin / GHSR-1a receptor activation (Ipamorelin)

This makes the combo highly relevant for:

  • GH pulsatility models
  • Endocrine-axis mapping
  • CNS–pituitary signalling research

What Is Tesamorelin?

Tesamorelin is a synthetic GHRH analogue engineered to bind GHRH receptors and stimulate endogenous growth hormone release in a controlled, receptor-specific manner.

It is structurally different from CJC-1295 and is sometimes used as a single-agent GHRH analogue in:

  • Metabolic research models
  • Lipid-redistribution studies (preclinical context)
  • Endocrine and hypothalamic–pituitary axis research

Tesamorelin is essentially the “GHRH only” arm of this comparison.

Mechanism Comparison: CJC/Ipamorelin vs Tesamorelin

1. Receptor Targets

CJC-1295 / Ipamorelin combo

  • CJC-1295 → GHRH receptor
  • Ipamorelin → GHSR-1a (ghrelin receptor)

Tesamorelin

  • Tesamorelin → GHRH receptor (no GHSR-1a activity)
Research framing:
CJC/Ipamorelin → dual-pathway GH-related stimulation
Tesamorelin → single-pathway, GHRH-focused analogue

2. Research Questions Typically Asked

CJC-1295 / Ipamorelin models

Researchers often study:

  • Patterns of GH pulse frequency and amplitude
  • Interplay between GHRH and ghrelin pathways
  • Combined pituitary and hypothalamic signalling

Tesamorelin models

Researchers often focus on:

  • Isolated GHRH receptor dynamics
  • Metabolic and lipid-modulation frameworks
  • Longer-term GH axis behaviour with a single analogue

3. Complexity vs. Specificity

  • CJC-1295/Ipamorelin tends to be used when labs want a more complex, multi-pathway model involving both GHRH and ghrelin-related signalling.
  • Tesamorelin is used when the goal is clear, isolated GHRH-pathway research without GHSR-1a involvement.

Molecular & Research Profile Overview

Feature
CJC-1295 + Ipamorelin
Tesamorelin
Category
GHRH analogue + GHRP combo
GHRH analogue
Main receptors
GHRH-R (CJC) + GHSR-1a (Ipa)
GHRH-R
Research focus
GH pulsatility, multi-pathway endocrine models
GHRH-specific, metabolic/endocrine models
Use pattern
Often in combo protocols
Often as standalone analogue
Study environment
In-vitro / ex-vivo models
In-vitro / ex-vivo models

Why Researchers Compare Them

Canadian labs compare CJC-1295/Ipamorelin vs Tesamorelin to answer questions like:

  • How does combined GHRH + GHSR-1a stimulation differ from pure GHRH stimulation?
  • Are there differences in pulse frequency vs amplitude in controlled models?
  • How do metabolic readouts differ between dual-pathway and single-pathway stimulation in preclinical systems?

This makes comparison pages like this important as a neutral map of mechanisms, not as a dosing or protocol guide.

Canadian Researcher Considerations

For all three compounds (CJC-1295, Ipamorelin, Tesamorelin), Canadian labs typically require:

  • ≥99% purity
  • Full COA with HPLC and identity confirmation
  • Clear batch and lot numbers
  • Domestic, tracked shipping
  • Professional, research-grade presentation
Documentation + traceability help reduce confounding variables in endocrine-axis experiments where small inconsistencies can skew interpretation.

Compliance Reminder

All compounds discussed are supplied strictly for scientific, laboratory, and in-vitro research use only.
No human or veterinary use is implied or supported.
No dosing, safety, or therapeutic claims are made.

Explore More Growth-Hormone–Related Research Guides

US Research Resources

Peptides in the United States
https://www.hollywoodpeptides.co/peptides-usa/
An overview for US-based researchers explaining how research peptides are sourced from Canada, including documentation standards, quality verification, and cross-border considerations.

US Peptide Research Regulations
https://www.hollywoodpeptides.co/peptide-research-regulations-usa/
A clear explanation of how research peptides are treated under US regulatory frameworks, including FDA oversight, import screening, labeling requirements, and compliance considerations.

Shipping Peptides to the USA
https://www.hollywoodpeptides.co/shipping-peptides-to-usa/
A transparent guide outlining what US researchers can expect when shipping peptides from Canada, including customs review, delivery timelines, and potential shipment outcomes.

Disclaimer

This product is provided strictly as a research chemical. It is intended solely for laboratory use and in vitro studies, not for human or animal consumption. All information presented on this website is offered for educational and scientific reference only. Any form of bodily introduction, direct or indirect, is prohibited by law. Handling of this product should be performed only by qualified, licensed professionals. This item is not classified as a drug, food, or cosmetic, and must not be misrepresented, marketed, or used as such.

FAQ

The main difference lies in pathway breadth. Tesamorelin is a stabilized GHRH analogue that acts on the GHRH receptor to model GHRH-focused signalling. The CJC-1295/Ipamorelin blend is a dual-pathway model: CJC-1295 targets the GHRH receptor, while Ipamorelin targets the ghrelin receptor (GHSR-1a), enabling comparative study of multi-receptor signalling in controlled systems.
Tesamorelin is typically selected when the study goal is isolated GHRH-pathway research without ghrelin/GHSR-1a involvement—useful for experiments aiming to reduce pathway complexity and focus on receptor-specific dynamics.
Research handling generally emphasizes stable, cool storage for lyophilized materials, moisture control, minimized temperature swings, and standardized SOPs for reconstitution/handling to reduce variability across assays and batches.
This page is intentionally not a safety, dosing, or clinical-effects guide. In research documentation, “side effects” are not treated as a primary framing because these compounds are designated for laboratory and in-vitro use only. If safety data is reviewed at all, it is handled in a controlled, literature-based context without implying human use.
Verification discussions typically emphasize ≥99% purity verification, lot-specific COAs, identity confirmation (e.g., MS), and batch traceability. For general documentation expectations, see: Purity Standards, Lab Results / COAs, How to Read a COA.
Age Verification!

*By continuing, you confirm eligibility and legal compliance.

No
Yes
0%
free-delivery